Leaving the study early · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).
Global state: Average endpoint global state score (clinically improved) (no data) · patients with schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects ‐ important extrapyramidal adverse effects · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with chlorprothixene (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review